Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/The Body PRO Covers CROI 2009, February 8-11, 2009
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

More Monotherapy Data Underscore Its Potential to Harm

February 21, 2009

In a poster presentation at CROI 2009 in Montreal, Canada, the MOST study showed poor results using Kaletra alone (called monotherapy) to control HIV levels. There was such a high rate of early failure (viral breakthrough) that the study was stopped early due to safety concerns.

This randomized study was designed to evaluate how well Kaletra alone suppressed HIV in the cerebral spinal fluid and genital tract. Safety and effectiveness were evaluated as well as identifying what (if any) markers predicted failure. After 48 weeks on three-drug therapy, people were offered Kaletra alone. The failure protocol was set at 6 or more volunteers failing on Kaletra alone out of the first 30 enrolled.

In September 2008, the protocol committee stopped the study due to 6 volunteers showing detectable HIV levels in blood. By that time, 60 had been enrolled and 29 of them were taking the single-drug therapy. People who experienced viral breakthrough while on Kaletra alone had generally lower nadir (lowest ever) CD4 counts (below 100). Also, several had symptoms of problems with their central nervous systems.

Advertisement
As noted in our coverage from the 2008 ICAAC on two other similar studies (www.projectinform.org/news/08_icaac/102708c.shtml), Project Inform believes these types of studies should no longer be attempted as these monotherapy regimens continue to show dramatic virologic failures. Not only is this a poor use of resources that could be better spent on more pressing questions, the strategy puts study participants at great risk for treatment failure, which may unduly complicate their future regimens.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
CROI 2009 Newsroom



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement